232 related articles for article (PubMed ID: 21051889)
1. From evidence to rationale: cardiovascular protection by angiotensin II receptor blockers compared with angiotensin-converting enzyme inhibitors.
Böhm M; Baumhäkel M; Mahfoud F; Werner C
Cardiology; 2010; 117(3):163-73. PubMed ID: 21051889
[TBL] [Abstract][Full Text] [Related]
2. Rationale, design, and baseline characteristics of 2 large, simple, randomized trials evaluating telmisartan, ramipril, and their combination in high-risk patients: the Ongoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial/Telmisartan Randomized Assessment Study in ACE Intolerant Subjects with Cardiovascular Disease (ONTARGET/TRANSCEND) trials.
Teo K; Yusuf S; Sleight P; Anderson C; Mookadam F; Ramos B; Hilbrich L; Pogue J; Schumacher H;
Am Heart J; 2004 Jul; 148(1):52-61. PubMed ID: 15215792
[TBL] [Abstract][Full Text] [Related]
3. The ONTARGET/TRANSCEND Trial Programme: baseline data.
Sleight P
Acta Diabetol; 2005 Apr; 42 Suppl 1():S50-6. PubMed ID: 15868120
[TBL] [Abstract][Full Text] [Related]
4. The ongoing telmisartan alone and in combination with ramipril global endpoint trial program.
Unger T
Am J Cardiol; 2003 May; 91(10A):28G-34G. PubMed ID: 12781906
[TBL] [Abstract][Full Text] [Related]
5. From the HOPE to the ONTARGET and the TRANSCEND studies: challenges in improving prognosis.
Yusuf S
Am J Cardiol; 2002 Jan; 89(2A):18A-25A; discussion 25A-26A. PubMed ID: 11835907
[TBL] [Abstract][Full Text] [Related]
6. Angiotensin II and trials of cardiovascular outcomes.
Sleight P
Am J Cardiol; 2002 Jan; 89(2A):11A-16A; discussion 16A-17A. PubMed ID: 11835905
[TBL] [Abstract][Full Text] [Related]
7. Challenges in improving prognosis and therapy: the Ongoing Telmisartan Alone and in Combination with Ramipril Global End point Trial programme.
Zimmermann M; Unger T
Expert Opin Pharmacother; 2004 May; 5(5):1201-8. PubMed ID: 15155118
[TBL] [Abstract][Full Text] [Related]
8. Rationale and design of the cardiac magnetic resonance imaging substudy of The ONTARGET Trial Programme.
Anderson C
J Int Med Res; 2005; 33 Suppl 1():50A-57A. PubMed ID: 16222900
[TBL] [Abstract][Full Text] [Related]
9. Sexual function, satisfaction, and association of erectile dysfunction with cardiovascular disease and risk factors in cardiovascular high-risk patients: substudy of the ONgoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial/Telmisartan Randomized AssessmeNT Study in ACE-INtolerant Subjects with Cardiovascular Disease (ONTARGET/TRANSCEND).
Böhm M; Baumhäkel M; Probstfield JL; Schmieder R; Yusuf S; Zhao F; Koon T;
Am Heart J; 2007 Jul; 154(1):94-101. PubMed ID: 17584560
[TBL] [Abstract][Full Text] [Related]
10. Hypertension treatment and implications of recent cardiovascular outcome trials.
Weber MA
J Hypertens Suppl; 2006 Apr; 24(2):S37-44. PubMed ID: 16601560
[TBL] [Abstract][Full Text] [Related]
11. Angiotensin II receptor antagonists and heart failure: angiotensin-converting-enzyme inhibitors remain the first-line option.
Prescrire Int; 2005 Oct; 14(79):180-6. PubMed ID: 16285075
[TBL] [Abstract][Full Text] [Related]
12. Cardiovascular risk reduction by reversing endothelial dysfunction: ARBs, ACE inhibitors, or both? Expectations from the ONTARGET Trial Programme.
Ruilope LM; Redón J; Schmieder R
Vasc Health Risk Manag; 2007; 3(1):1-9. PubMed ID: 17583170
[TBL] [Abstract][Full Text] [Related]
13. Rationale for double renin-angiotensin-aldosterone system blockade.
Unger T; Stoppelhaar M
Am J Cardiol; 2007 Aug; 100(3A):25J-31J. PubMed ID: 17666194
[TBL] [Abstract][Full Text] [Related]
14. A multicenter, 14-week study of telmisartan and ramipril in patients with mild-to-moderate hypertension using ambulatory blood pressure monitoring.
Lacourcière Y; Neutel JM; Davidai G; Koval S
Am J Hypertens; 2006 Jan; 19(1):104-12. PubMed ID: 16461201
[TBL] [Abstract][Full Text] [Related]
15. The HOPE Study (Heart Outcomes Prevention Evaluation).
Sleight P
J Renin Angiotensin Aldosterone Syst; 2000 Mar; 1(1):18-20. PubMed ID: 11967789
[TBL] [Abstract][Full Text] [Related]
16. [Vascular patient with high infarction risk. Does the AT-1 blocker protect as well as an ACE inhibitor?].
MMW Fortschr Med; 2003 Dec; 145(51-52):39. PubMed ID: 14974331
[No Abstract] [Full Text] [Related]
17. Glucose levels predict hospitalization for congestive heart failure in patients at high cardiovascular risk.
Held C; Gerstein HC; Yusuf S; Zhao F; Hilbrich L; Anderson C; Sleight P; Teo K;
Circulation; 2007 Mar; 115(11):1371-5. PubMed ID: 17339550
[TBL] [Abstract][Full Text] [Related]
18. Debate: angiotensin-converting enzyme inhibitors versus angiotensin II receptor blockers--a gap in evidence-based medicine.
Ball SG; White WB
Am J Cardiol; 2003 May; 91(10A):15G-21G. PubMed ID: 12781904
[TBL] [Abstract][Full Text] [Related]
19. Ramipril for the prevention and treatment of cardiovascular disease.
Vuong AD; Annis LG
Ann Pharmacother; 2003 Mar; 37(3):412-9. PubMed ID: 12639174
[TBL] [Abstract][Full Text] [Related]
20. The 24-hour blood pressure pattern: does it have implications for morbidity and mortality?
Weber MA
Am J Cardiol; 2002 Jan; 89(2A):27A-33A. PubMed ID: 11835909
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
